Position of the Transparency Council – Opdivo (nivolumab)

At its meeting on 18 July 2022 the Transparency Council adopted Position No. 65/2022  on the evaluation of the drug Opdivo (nivolumab) as part  of the drug programme: “Treatment of non-small or small cell lung cancer (ICD-10 C 34) and treatment of pleural mesothelioma (ICD-10 C45)”.

Publication in Public Information Bulletin (BIP)